Business
Brooks Automation Announces Realignment of its Life Sciences Segment
CHELMSFORD, Mass., March 10, 2020 /PRNewswire/ -- Brooks Automation, Inc. (Nasdaq: BRKS), announced today new leadership appointments and a realignment of its
About this update from Azenta, Inc.
[{"type":"text","content":"CHELMSFORD, Mass., March 10, 2020 /PRNewswire/ -- Brooks Automation, Inc. (Nasdaq: BRKS), announced today new leadership appointments and a realignment of its Life Sciences business organization to enhance capabilities and provide for optimal growth and efficiency.\nOver the past decade, Brooks has undergone a transformation from a pure semiconductor automation company to a company addressing two distinct growth segments, with leadership positions in both the Semiconductor equipment and the Life Sciences industries. Over the years, the company has evolved its organization to support the rapid growth of its businesses and to provide customer focused leadership. As an important step in this transformation, in September 2019, Steve Schwartz, president and CEO of Brooks, assumed the interim role of the Life Sciences general manager with deliberate intention to reshape the segment. Today, the Company announced this transitional step has culminated in the realignment of its operating units and the naming of new segment leadership.\nSince the acquisition of GENEWIZ in November 2018, Brooks Life Sciences has been composed of two operating units, Sample Management and GENEWIZ. The Company is realigning these operations into the newly formed Life Sciences Services and Life Sciences Products business units:\nLife Sciences Services will combine GENEWIZ genomic services with Biostorage sample management services under the leadership of Dr. Amy Liao, President of Life Sciences Services. Combining these two service-based businesses will leverage the potential for synergies as customers adopt outsourced services to manage a broad variety of sample-based services including gene sequencing, gene synthesis, lab analysis, sample kitting and preparation, transportation, and storage. Dr. Liao, as the co-founder, former CEO and current President of GENEWIZ, has been an industry insider for more than 20 years where she has accumulated substantial knowledge of the researcher's challenges and the increasing value of the sample assets.\nLife Sciences Products will be composed of the sales and delivery of all products, including the large automated ultra-cold stores, automated cryogenic storage systems, and consumables and instruments. This business unit will also include the post-warranty service support of its products. Robin Vacha has been appointed Sen...